{"id":"NCT03392974","sponsor":"BioMarin Pharmaceutical","briefTitle":"Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg","officialTitle":"A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII at a Dose of 4E13vg/kg in Hemophilia A Patients With Residual FVIII Levels â‰¤1IU/dL Receiving Prophylactic FVIII Infusions","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-14","primaryCompletion":"2019-05-22","completion":"2023-06-05","firstPosted":"2018-01-08","resultsPosted":"2021-10-08","lastUpdate":"2023-10-03"},"enrollment":1,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemophilia A"],"interventions":[{"type":"BIOLOGICAL","name":"Valoctocogene Roxaparvovec","otherNames":["BMN 270"]}],"arms":[{"label":"Valoctocogene Roxaparvovec Open Label","type":"EXPERIMENTAL"}],"summary":"This Phase III clinical study will assess the efficacy of BMN 270 defined as FVIII activity, during weeks 49-52 following intravenous infusion of BMN 270 and assess the impact of BMN 270 on usage of exogenous FVIII replacement therapy and the number of bleeding episodes from week 5 to week 52.","primaryOutcome":{"measure":"Change of the Median Factor VIII (FVIII) Activity","timeFrame":"Week 52","effectByArm":[{"arm":"BMN 270 4E13 vg/kg","deltaMin":4.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":1},"commonTop":["Pyrexia","Hepatocellular injury","Nasopharyngitis","Alanine aminotransferase increased","Myalgia"]}}